Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial
Trending
- Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced Ca2+ activity
- Advancement of NK cell-mediated pancreatic cancer therapy through high-throughput screening
- PM vows Durham breast cancer inquiry and Cleveland Police boost
- Stoke-on-Trent prostate screening event attended by 500 men
- Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM
- Nursing Strategies for the 3 First-Line Regimens in EGFR-Mutated NSCLC
- Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders
- How Can Literature and Peer Review Impact an Oncology Fellow’s Career?
Saturday, September 26
Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial
By NewsCancer
